Recombinant Human EDA protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg4242

---

Validation Data Gallery

• 

  Purity of Recombinant Human EDA was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human EDA protein Glu63-Ser391 (Accession# Q92838-1) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 1896
• Accession: Q92838-1
• PredictedSize: 62.0 kDa
• SDS-PAGE: 35-40 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

EDA (ectodysplasin A), which belongs to the tumor necrosis factor (TNF) family, causes cell death, proliferation, or differentiation. EDA primarily regulates the induction, morphogenesis, and/or maintenance of structures of cutaneous origin (e.g., teeth, hair, sweat glands, and several other glands). Mutations in the gene responsible for EDA signaling result in hypohidrotic ectodermal dysplasia (HED), an A congenital genetic disorder accompanied by malformations of the skin attachments. Recent studies have shown that EDA and its receptors regulate cancer cell proliferation, apoptosis, differentiation, and migration, which may regulate tumorigenesis and cancer progression. The EDA pathway has also been shown to be involved in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and type II diabetes by regulating glucose and lipid metabolism. (PMID: 36012178)

References:

1. Yang R,et al. Int J Mol Sci. 2022;23(16):8911.                                                          
2. Ou S, et al. Int J Mol Sci. 2022;23(24):15700.                                                          
3. Deng X,et al. J Diabetes Res. 2023;2023:5087761.